Pfizer wins FDA priority review for Hympavzi label expansion

Pfizer (PFE) announced on Friday that the U.S. Food and Drug Administration granted priority review for a marketing application seeking a label expansion for its hemophilia therapy, Hympavzi. The New ...
Becker's Hospital Review

Pfizer gets FDA priority review for pediatric hemophilia treatment

Pfizer gets FDA priority review for Hympavzi to treat children 6-11 with hemophilia A or B, expanding current U.S. approvals.

Pfizer Gets FDA Priority Review for Expanded Hympavzi Approval

Pfizer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its Hympavzi hemophilia drug for two patient populations with significant medical need ...
FiercePharma

ASH: Pfizer, aiming to level the hemophilia playing field, trots out new Hympavzi data

Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its competition with Sanofi’s Qfitlia and Novo Nordisk’s Alhemo. After an FDA ...
MM&M

Pfizer’s birth control injection has a new safety label, reflecting potential brain tumors

Pfizer’s battle over the safety label for its birth control injection has finally come to a close. The pharma giant announced that the Food and Drug Administration approved its new safety warning ...